2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Biological Processes, Immune Mechanism, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Diseases, Bleeding and Clotting, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, AML, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

5981 Outcomes of allogeneic hematopoietic stem cell transplantation with intermediate - intensity conditioning with fludarabine, busulfan and melphalan in older adults (≥55 Years) with AML and high-risk MDS: A Chinese multicenter retrospective study

Wenhui Gao, MD, Lining WANG, MD2, Xiaojin Wu, MD3, Yali Zhou4, Guoqiang Li5, Sanbing Wang, MD6, Chuanhe Jiang7, Lan Sun8, Hao Zhang9, Chunkang Chang10, Su Li11, Houcai Wang12, Ruihong Dong13, Haitao Xu14, Xiuli Hong15, Ming Wan16, ling Wang17, Jieling Jiang18, Chun Wang19, Jiong Hu, MD20
1 Shanghai Institute of Hematology, Department of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China
2 Shanghai Institute of Hematology, Department of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China
3 The First Affiliated Hospital of Soochow University, suzhou, China
4 Department of Hematology, 923rd Hospital of the Joint Logistics Support Force, Nanning, China, Nanning, China
5 Shenzhen People’s Hospital ( The Second Clinical Medical College,Jinan University;The First Affiliated Hospital, Southern University of Science and Technology ) Hematology, Shenzhen, China
6 Department of Hematology, The 920th Hospital of Joint Logistics Support Force of the People’s Liberation Army of China, Kunming, China, Kunming, China
7 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 Department of hematology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
9 Affiliated Hospital of Jining Medical University, Jining, China
10 Shanghai Sixth People's Hospital, Shanghai Jiaotong University school of Medicine, Shanghai, China
11 Department of Hematology, Go Broad Health Center, Shanghai Zhaxin Hospital, Shanghai, China, Shanghai, China
12 Department of Hematology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China, Shanghai, China
13 Department of Hematology, The Eighth Affiliated Hospital of Southern Medical University (The First People's Hospital of Shunde Foshan), Foshan, Guangdong, China, Guangdong, China
14 Anqing Municipal Hospital, Anqing, China
15 Department of Hematology, Zhongshan Hospital of Xiamen University , Xiamen, Fujian China, Xiamen, China
16 Shanghai Clinical Research Center (SCRC), 380 Feng lin Road, Shanghai, China, Shanghai, China
17 Shanghai Institute of Hematology, Rui Jin Hospital, Shanghai, China
18 Shanghai Institute of Hematology, Rui Jin Hospital, Shanghai, China
19 Department of Hematology Go Broad Health Center Shanghai Zhaxin Hospital Shanghai China., Shanghai, China
20 Shanghai Institute of Hematology, Department of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China

Background

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only potentially curative therapy for older patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). However, reduced-intensity conditioning regimens may be associated with increased relapse due to insufficient antileukemic activity, whereas myeloablative regimens are often limited by toxicity in older adults. Intermediate-intensity conditioning incorporating multiple alkylating agents may provide a balance between disease control and tolerability. We evaluated transplantation outcomes of older patients with AML and high-risk MDS receiving fludarabine, busulfan, and melphalan (FBM) conditioning.

Methods

This multicenter retrospective study included patients aged ≥55 years with AML or high-risk MDS who underwent first allo-HSCT after FBM conditioning between January 2020 and December 2024. Clinical characteristics, transplantation outcomes, and prognostic factors were analyzed. The primary endpoint was overall survival (OS). Secondary endpoints included disease-free survival (DFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and graft-versus-host disease (GVHD). OS and DFS were estimated using Kaplan–Meier methods. CIR and NRM were evaluated using competing-risk analysis with Fine-Gray regression. Multivariable Cox and Fine-Gray regression models were used to identify factors associated with transplantation outcomes.

Result

A total of 111 patients were included, with a median age of 59 years (range, 55–69). AML accounted for 73.0% (n=81) and high-risk MDS for 27.0% (n=30) of patients. Most patients received haploidentical transplantation (82.9%, n=92). After a median follow-up of 911 days, the estimated 1-year and 3-year OS rates were 89.1% (95%CI 83.5-95.1%) and 76.3% (95%CI 68.6-84.9%), respectively. The corresponding DFS rates were 87.3% (95%CI 81.3-93.7%) and 75.8% (95%CI 68.1-84.3%).

The cumulative incidence of relapse was 5.5% (95%CI 1.8-9.3%) at 1 year and 7.7% (95%CI 3.3-12.1%) at 3 years, while NRM was 11.7% (95%CI 6.5-17.1%) and 19.3% (95%CI 12.6-25.7%), respectively. Multivariable analysis demonstrated that high-risk Disease Risk Index (DRI) was independently associated with inferior OS (HR, 3.65; 95% CI, 1.55–8.59; P=0.003) and DFS (HR, 3.34; 95% CI, 1.51–7.42; P=0.003). High-risk DRI was also associated with increased NRM (SHR, 3.00; 95% CI, 1.06–8.48; P=0.038). In contrast, age ≥60 years was not associated with inferior survival outcomes.

Conclusion
Intermediate-intensity FBM conditioning provided favorable disease control with low relapse incidence and acceptable non-relapse mortality in older adults undergoing allo-HSCT for AML and high-risk MDS. High-risk disease burden, rather than chronological age alone, was the major determinant of transplantation outcomes. These findings support the feasibility of FBM conditioning as a transplant strategy for selected older patients.

Wenhui Gao, MD: No relevant conflicts of interest to declare.